ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO <i>FONSECAEA PEDROSOI</i>

<jats:title>Abstract</jats:title><jats:p>The efficacy and tolerability of itraconazole in chromoblastomycosis due to <jats:italic>Fonsecaea pedrosoi</jats:italic> were evaluated in a non‐comparative open clinical trial in 19 Brazilian patients with histopathologically and mycologically proven active chromoblastomycosis. Patients were classified in terms of severity and received itraconazole at the dosage of 200 to 400 mg per day until previously described criteria of cure have been reached. Clinical, mycologic, histopathologic, and laboratory evaluations were performed before, during, and after therapy. The plasma levels of itraconazole and the <jats:italic>in vitro</jats:italic> susceptibility of the isolates were determined in 15 cases. Clinical and biologic cure were achieved by eight patients (42%) having mild to moderate disease, after a mean duration of therapy of 7.2 months (3.2–29.6 months). Sterile scarred lesions were observed in a post‐therapy follow‐up lasting on average 9.6 months that was carried out in this subgroup. Clinical cure alone occurred after a mean period of 25.1 months of treatment (16–30.5 months) in seven patients (36%) with moderate to severe disease. Finally, clinical improvement was obtained in four patients (21%) with severe lesions after a mean treatment time of 17.6 months (10.7–22.5 months). All patients responded favorably to itraconazole therapy. No significant side effects nor biochemical alteration during this trial were important enough to interrupt the treatment. Our results support those of previous trials, suggesting that itraconazole is an effective compound against chromoblastomycosis due to <jats:italic>Fonsecaea pedrosoi</jats:italic>.</jats:p>